Is Ipamorelin FDA-Approved? Its FDA and 503A Status in 2026

No. Ipamorelin is not an FDA-approved drug and never has been. No company has brought an ipamorelin product through FDA’s approval pathway, and there is no approved brand to compare it with.

On compounding, ipamorelin is on none of the three categories on FDA’s 503A list, which is still dated May 14, 2026. Category 1 allows compounding during review; Category 2 flags a significant safety risk; Category 3 means a nomination lacked support. Ipamorelin’s nomination was withdrawn. Being on no list is not the same as being permitted, and it is not the same as being flagged.

In 2023, FDA was reported to have placed a group of peptides, ipamorelin among them, in interim Category 2, the category that signals a significant safety risk in compounding. In September 2024 ipamorelin was reported removed from Category 2 after its nominator withdrew the nomination. The same report covered CJC-1295, AOD-9604, thymosin alpha-1 and selank.

That removal is often retold as "the ban was lifted". It was not a move to Category 1, the category that allows compounding while FDA reviews an ingredient. Ipamorelin now sits on no category of the list at all. That is a quieter position than Category 2, and it gives no affirmative allowance.

Ipamorelin and MK-677 (ibutamoren) are often compared because both are discussed as growth-hormone secretagogues. Their regulatory positions are opposite. Ibutamoren mesylate is on FDA’s current 503A Category 2, the list of substances FDA says raise significant safety risks and should not be compounded. Ipamorelin is on no list.

They are also different kinds of molecule. MK-677 is a small molecule, not a peptide, although it is often sold under the "peptide" label. Neither is FDA-approved.

Ipamorelin is most often discussed alongside CJC-1295, as a single "CJC/ipa" protocol. The combination has no regulatory status of its own, and our evidence index found no rigorous human trial of the pairing. Each component has small early-phase human data showing growth-hormone release. Neither has completed clinical-outcome trials, and the pair has never been trialled together.